Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06121466 · ClinicalTrials.gov registry record · Phase 4
Effect of Abdominal Wall Injections on Abdominal Pain
A Phase 4 study of Anterior Cutaneous Nerve Entrapment Syndrome, sponsored by Oregon Health and Science University.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 45
- Enrollment target
- 2
- Study locations
NCT06121466: Recruiting Phase 4 study of Anterior Cutaneous Nerve Entrapment Syndrome, sponsored by Oregon Health and Science University.
NCT06121466 is a Phase 4 study of Anterior Cutaneous Nerve Entrapment Syndrome that is actively recruiting participants, run by Oregon Health and Science University. The registered enrollment target is 45 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (91% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06121466, a Phase 4 study of Anterior Cutaneous Nerve Entrapment Syndrome, is actively recruiting participants, sponsored by Oregon Health and Science University.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 45 participants
- Enrollment target
- 2
- Study locations
Study Summary
This is a prospective cohort study of outpatient adults with chronic abdominal wall pain receiving abdominal wall injections, as part of their usual care, with lidocaine. Subjects will be recruited at the outpatient gastroenterology clinic at OHSU.
Primary Outcome
Improvement is defined as a 50% reduction in baseline pain score measured using an 11-point numeric scale where 0 is no pain and 10 is the worst pain the patient has every felt.
Conditions Studied
Interventions
- DRUG Abdominal wall injections with lidocaine 2%
Study Locations (2)
Oregon
- OHSU - Portland
- Oregon Health Sciences University - Portland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2023-01-01 |
| Est. Completion | 2025-12 |
| Phase | Phase 4 |
What NCT06121466 shows while recruiting
NCT06121466 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 45 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (91% lower).
The record links to 1 condition, with Anterior Cutaneous Nerve Entrapment Syndrome appearing as the primary indexed condition, and to 1 intervention - of which Abdominal wall injections with lidocaine 2% is the first listed.
NCT06121466 reports a single indexed study location in Oregon.
Frequently Asked Questions
What is clinical trial NCT06121466 about?
NCT06121466 is a clinical study titled "Effect of Abdominal Wall Injections on Abdominal Pain". This is a prospective cohort study of outpatient adults with chronic abdominal wall pain receiving abdominal wall injections, as part of their usual care, with lidocaine. Subjects will be recruited at the outpatient gastroenterology clinic at OHSU.
What is the current status of trial NCT06121466?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 45 participants. The study started on 2023-01-01. Estimated completion is 2025-12.
What conditions does trial NCT06121466 study?
This clinical trial studies the following conditions: Anterior Cutaneous Nerve Entrapment Syndrome.
What interventions are being tested in trial NCT06121466?
The interventions under investigation include: Abdominal wall injections with lidocaine 2% (DRUG).
Who is sponsoring clinical trial NCT06121466?
This trial is sponsored by Oregon Health and Science University, which has 546 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06121466 being conducted?
This trial has 2 study locations across Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06121466's enrollment target sits among peer trials
45 1354th of 2000 higher than 639 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00804154 · 45 participants · Phase 1
Resiniferatoxin to Treat Severe Pain Associated With Advanced Cancer
- NCT01851694 · 45 participants · NA
Beta-cell Response to Incretin Hormones in Cystic Fibrosis
- NCT02896335 · 45 participants · Phase 2
Palbociclib and Pembrolizumab In Central Nervous System Metastases
- NCT03454035 · 45 participants · Phase 1
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI